Neue Suche | Kongressdetail
mail
Druckansicht
 
 

4th Annual Chronic Kidney Disease Drug Development Summit (CKD)

Evvnt Promotion / evvnt
-
01.03.2022 - 03.03.2022  Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 08:00 - 17:00
 
Kongressthemen
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
Kongressorganizer (PCO)
Hanson Wade
Anmerkungen
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.
 

Anfragen und Anmeldung:

https://go.evvnt.com/915880-2?pid=4832
Herr Jessica Durston
 
Kategorien
Allgemeinmedizin
Sprache
Englisch
Kongressgebühr
USD 2099.0 - USD 4996.0
Teilnehmer erwartet
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
 
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."

AMREF - African Medical and Research FoundationHelix - Forschung & Beratung WienCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioAlumni Club Medizinische Universität WienCharité International AcademyOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Ärztekammer für WienAGEM - Arbeitsgemeinschaft Ethnologie und Medizin